- Unicycive gets second CRL for kidney drug as manufacturing woes continueUnicycive Therapeutics’ chronic kidney disease drug was rejected by the FDA for a second time over persistent issues at a third-party contract manufacturer. The company’s phosphate binder drug ox…Endpoints · 26d ago↗ source
- Half of states sue over Medicaid work requirementsFDA peptide panelists, a new study on Covid and flu shots, and more health news from Morning RoundsSTAT · 26d ago↗ source
- Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe diseaseSanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US. The French pharma is looking…